The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients With Eosinophilic Granulomatosis With Polyangiitis
Targeting the interleukin-5 receptor with benralizumab or circulating interleukin-5 with mepolizumab are effective OGC-sparing strategies in patients with EGPA.
Authors
- Sofia Necander
- NADER A. KHALIDI (ORCID: https://orcid.org/0000-0002-8270-2617)
- ARNAUD AB BOURDIN (ORCID: https://orcid.org/0000-0002-4645-5209)
- Ying Fan (ORCID: https://orcid.org/0000-0003-0044-6750)
- Anat Shavit
- Eva Rodríguez‐Suárez
- Christopher McCrae (ORCID: https://orcid.org/0000-0001-7184-9069)
- David R.W. Jayne (ORCID: https://orcid.org/0000-0002-1712-0637)
- Florence Roufosse (ORCID: https://orcid.org/0000-0002-5288-0375)
- Lena Börjesson Sjö
- Bernhard Hellmich (ORCID: https://orcid.org/0000-0002-8014-1801)
- Claire Walton
- Peter A. Merkel (ORCID: https://orcid.org/0000-0001-9284-7345)
- Michael E. Wechsler
Institutions
- AstraZeneca (United Kingdom) (GB)
- Centre National de la Recherche Scientifique (FR)
- Université Libre de Bruxelles (BE)
- Inserm (FR)
- Université de Montpellier (FR)
- University of Cambridge (GB)
- Erasmus Hospital (BE)
- National Jewish Health (US)
- Cambridge School (PT)
- Centre Hospitalier Universitaire de Montpellier (FR)
- Universitätsklinikum Tübingen (DE)
- Bridge University (SS)
- Real Time Analyzers (United States) (US)
- AstraZeneca (Finland) (FI)
- AstraZeneca (Spain) (ES)
- AstraZeneca (Germany) (DE)
- St. Joseph’s Healthcare Hamilton (CA)
- University of Pennsylvania (US)
- University of Colorado Denver (US)
- McMaster University (CA)
Publication Details
- Journal
- Arthritis & Rheumatology
- Published
- 2025-09-22
- DOI
- https://doi.org/10.1002/art.43398
- Citations
- 2
- Primary Topic
- Urticaria and Related Conditions
- Type
- article
- Field-Weighted Citation Impact
- 3.34
Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Sanofi
- Teva Pharmaceutical Industries
- Regeneron Pharmaceuticals
- InflaRx
- Genentech
- Chugai Pharmaceutical